Unleashing Innovation: The Role of Bispecific Antibodies in Managing Diffuse Large B-Cell Lymphoma
This dynamic course focuses on the exchange of best practices regarding the use of bispecifics in patients with R/R DLBCL including patient eligibility. Through this interactive, small-group activity, participants will review brief modules and patient cases to identify signs and symptoms of toxicities experienced while receiving treatment with bispecific antibodies for R/R DLBCL and also integrate protocols to manage CRS and ICANS effectively when managing patients. The group will gather for a live discussion via Zoom to share and exchange ideas on this topic.
Unlocking the Potential: Advancements in ADC Therapy for Metastatic Triple Negative and HR+/HER2- Breast Cancer Treatment
This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HR+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.
